Cardinal Health vs Align Technology
Side-by-side comparison of AI visibility scores, market position, and capabilities
Dublin OH pharmaceutical distribution (NYSE: CAH) $230B+ revenue; specialty pharma GLP-1 distribution tailwind, at-Home Solutions growth, medical divestiture to Medline competing with McKesson and Cencora.
About
Cardinal Health, Inc. is a Dublin, Ohio-based healthcare distribution and medical products company — publicly traded on the New York Stock Exchange (NYSE: CAH) as an S&P 500 Health Care component — distributing pharmaceutical products to pharmacies, hospitals, and healthcare providers, and manufacturing and distributing medical and surgical supplies through approximately 44,000 employees. In fiscal year 2025 (ending June 2025), Cardinal Health generated revenues exceeding $230 billion in its Pharmaceutical and Specialty Solutions segment — reflecting the company's role as a pass-through distributor of branded and generic pharmaceuticals at near-zero margin on drug cost, where Cardinal Health earns distribution fees and rebate income on enormous volumes. CEO Jason Hollar has executed a two-segment strategy focused on optimizing pharmaceutical distribution (Pharmaceutical and Specialty Solutions — $227B+ revenue at low margin) and growing medical products profitability (Global Medical Products and Distribution — higher-margin branded surgical products, Cardinal Health brand commodities, and at-Home Solutions). The 2024 divestiture of the medical segment's Cardinal Health Brand product line to Medline Industries for $1.1 billion simplified the medical segment focus toward specialty distribution and home healthcare supply. Cardinal Health's specialty pharmaceutical distribution (oncology, rheumatology, rare disease biologics through Cardinal Health Specialty Solutions) is a growing higher-margin subsegment as pharmaceutical manufacturers contract with specialty distributors for controlled dispensing of limited-distribution drugs.
San Jose clear aligner orthodontics inventor (NASDAQ: ALGN) at $3.23B 2024 revenue; 20 million Invisalign patient milestone Q1 2025 across 280,000+ doctors with iTero Lumina scanner competing with 3M Clarity for orthodontic clear aligner prescriptions.
About
Align Technology, Inc. is a San Jose, California-based global medical device company — publicly traded on NASDAQ (NASDAQ: ALGN) as an S&P 500 component — operating as the inventor of the Invisalign System and the world leader in clear aligner orthodontics, reaching 20 million Invisalign patients treated worldwide in Q1 2025 through a network of 280,000+ Invisalign-trained doctors across 100+ countries. In fiscal year 2024, Align reported $3.23 billion in total revenue with Q4 2024 revenue of $995.2 million (+4.0% year-over-year). Align's product portfolio comprises the Invisalign System of clear aligners, iTero intraoral digital scanners (including the iTero Lumina with 3X wider field of capture in a 50% smaller wand), and exocad CAD/CAM software for digital dental workflows. Manufacturing is based in Mexico with treatment planning performed in Costa Rica. CEO Joseph Hogan joined from GE Healthcare in 2015. Founded 1997 by Zia Chishti and Kelsey Wirth in San Jose.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.